P-86 Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial

Autor:	Y. Chen, Q. Fan, L. Zhang, J. Xu, M. Tao, X. Zhuang, J. Wu, J. Sheng, C. Du, B. Lv, S. Wang, S. Qin, F. Bi, D. Jiang
Rok vydání:	2020
Předmět:	Sorafenib Oncology PHASE II/III TRIAL medicine.medical_specialty business.industry Hematology medicine.disease Pharmacokinetics Hepatocellular carcinoma Internal medicine Medicine In patient Open label business medicine.drug
Zdroj:	Annals of Oncology. 31:S117-S118
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.04.168
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::82262db8f6280b793afa9f6db7d38c07 https://doi.org/10.1016/j.annonc.2020.04.168 Zobrazit plný text záznamu